Primary Outcome Measures Modification(s) in the immune blood markers of treated subjects on treatment. [ Time Frame: Assessment: between week 4 and 6 after the first dose of the treatment ] Modification(s) in the immune blood markers including cytokines, immune cells and serum autoantibody level of treated subjects. Modification(s) in the immune blood markers[…]
Mesothelioma
SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Primary Outcome Measures Determination of ORR for the combination of OT-101 and pembrolizumab in subjects [ Time Frame: approximately 24 months ] modified RECIST (mRECIST; v1.1) Secondary Outcome Measures PFS, DOR and 6-month and 12-month Overall Survival (OS) will be estimated in all subjects in the ITT population. [ Time Frame: approximately 18 months ] Progression-free Survival (PFS),[…]
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Primary Outcome Measures Dose-limiting Toxicity (DLT) [ Time Frame: 28 days ] DLTs will be assessed via CTCAE version 5.0 Inclusion Criteria Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 in dose escalation, 0 to 2 in dose expansion Has a life expectancy of >3 months Has a malignancy:[…]
Increasing Levels of Women are Dying from Mesothelioma
Over the past 20 years, the number of women dying from mesothelioma increased by 25 percent. This is happening even with less asbestos being used. Deaths in men have been falling, the reverse of what is happening in women. The information was published in the Morbidity and Mortality Weekly Report[…]
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years (CanBenefitII)
Primary Outcome Measures Recruitment Rate [ Time Frame: 24 weeks ] The Recruitment Rate will be assessed by the number of eligible patients approached vs the number of eligible patients consent for the study, providing a number of non-participations. This will be gathered as an aspect of feasibility. Retention Rate [ Time Frame: 24 weeks ] Retention rate[…]
Targeted Therapy is Showing Promising Results for Mesothelioma
Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease[…]
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Primary Outcome Measures Identify maximum tolerated dose (MTD) and evaluate the toxicities of LMB-100 administered by 90-minute normothermic, intrapleural perfusion in participants with mesothelin-positive MPM, or MPE from cancers that express mesothelin [ Time Frame: 21 days ] List of adverse event frequency, type, and grade Safety data based on toxicity grades and types[…]
Vudalimab for the Treatment of Mesothelioma
The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
— SMARTEST Trial—
Primary Outcome Measures CD8 TILs density / gross tumor volume (GTV) [ Time Frame: Up to five years ] The primary objective of the study is to demonstrate that low dose cyclophosphamide in combination with sub-ablative radiation can enhance the anti-tumoral immune response compared to sub-ablative radiation alone Secondary Outcome Measures Survival [ Time Frame: Up to[…]
